AMR situation in Europe: Strategy and vision Koen Van Dyck Head of Unit Bilateral International Relations Head Taskforce on AMR DG Health & Food Safety European Commission
According to data from 2011, 25 000 patients die annually as a result of infections caused by resistant bacteria in the EU. The costs incurred by drug resistant infections amount to an estimated 1.5 billion annually, due to increases in healthcare expenditure costs and productivity losses.
Link between antibiotic treatment and AMR
http://www.compoundchem.com/2014/09/08/antibiotics/
Deaths globally attributable to AMR every year (compared to other major causes of death) Annually 700,000 deaths globally as a result of some antibiotics no longer working Projected to increase to 10 million by 2050; this is higher than cancer
Action Plan against the rising threats from Antimicrobial Resistance for the period 2011-2016
Evaluation 2011-2016 Action Plan Main findings: The actions were relevant to address the problems identified in 2011 and are still relevant today. The Action plan acted as a symbol of political commitment, stimulated actions within Member States and strengthened international cooperation. The Action Plan provided a framework to guide and coordinate activities at international level, including monitoring/surveillance and R&D. Actions were appropriate in view of the EU and national competences Recommendation: AMR problem is persisting and continued action is needed. 7
Human health Achievements: CR Prudent use (2002): In total 21 EU/EEA Member States have a national action plan including topics such as the prudent use of antimicrobial agents CR Patient safety (2009): In total 29 EU/EAA Member States have national guidelines for infection prevention and control. The number of participating countries in the European Antibiotic Awareness Day grew from 32 in 2008 to 43 in 2013. Recommendation: Support and assist MS, because huge differences between MS still exist
Animal health Achievements: New regulatory framework on veterinary medicine and medicated feed Animal Health Regulation (Adopted March 2016) Decision on monitoring and reporting of AMR (2013): Improvement coverage and scope (e.g. species, substances) of data collected on bacteria in food producing animals and certain food Recommendation: Support and assist MS, because huge differences between MS still exist
International cooperation Achievements: WHO: global standards of AMR (EURL-AMR) WHO: improving medicines selection, prescribing, dispensing and use in the African, Caribbean and Pacific Group of States. OIE activities: the new global database TATFAR: Transatlantic Taskforce (US, EU, Canada, Norway) Result: increased information exchange, understanding of best approaches and practices, the development of peer relationships. Recommendation: Given the cross-border nature of AMR a strong EU voice at international level remains necessary in the future.
Research and development Achievements: Joint Programming Initiative: Strategic research agenda (22 countries involved) IMI: ''New Drugs for Bad Bugs'' (EUR 650 million) New financing instrument for infectious diseases ''InnovFin ID'' (EUR 200 million) Prize on the ''Better use of antibiotics'' (EUR 1 million) Recommendation: Continued coordination and collaboration of research and innovation is needed to increase the efficiency of R&D and boost the development of alternative treatments, rapid diagnostic tests, new antimicrobials and vaccines.
Eurobarometer AMR 2016 Key findings: Around a third of EU citizens have taken antibiotics in the last 12 months, with little change since the 2013 survey. Knowledge of use and effects of antibiotics has remained constant since 2013, although with pronounced country differences Information only reached a third of Europeans. Of these, a third changed their behaviour on using antibiotics. In total 35% of the Europeans are in favour of action at global and EU level.
EU action against AMR: next steps Making the EU a best practice region Supporting and assisting Member States developing national action plans Strengthen surveillance and monitoring Increasing public awareness on AMR Stimulating research & innovation Exploring new business models & incentives to sustain investment Stimulate research on new antimicrobial drugs, rapid-diagnostic tests, vaccines and alternatives Shaping global action outside the EU Partnering with WHO, OIE and FAO Supporting 3 rd countries Pursuing high-level political commitment; UN, G7, G20
Thank you very much for your attention